Malaria Machine

Those who understand frequency medicine know that malaria is completely unnecessary and crapper be eliminated in a some hours. Here is a organisation that crapper do it in 60 minutes for a light infection. Of instruction this a big hammer to crack the walnut. Much smaller devices crapper do the job. The good news is that someone is actually doing some testing.

A physician from one of the leading multi-million dollar malaria projects in the world told me at an MIT conference that if they even tested an electromagnetic device on a malaria patient their funding would be totally eliminated.


Dr. Clark Research Association - 28 Aug 2009
David Amrein, Naturopath

Malaria is a condition of which 500 million people are affected every year, with as many as 2.7 million dying, mostly children. Malaria is caused by a follower transmitted by mosquitoes in warm and break areas, especially in Africa. The parasites are becoming increasingly resistant against the available drugs. 

Prof Henry Lai at the University of Washington in Seattle studied the mechanism by which artemisinin, a natural compound used against the malaria parasite, works to kill the parasite. It has to do with the interaction of artemisinin with iron that is stacked within the parasite. Looking at the iron stacks, Prof. Lai wondered whether treatment with an oscillating attractable earth could maybe kill the parasite.

Lab tests were successful and Prof. Lai published his impact in 2000, hoping that others would take up the idea and develop units that could be used to treat malaria with attractable fields. Unfortunately, this did not happen.

I saw Prof. Lai's study some three years ago and was amazed that 6 years after publication, no one had developed any application of it! So I set out to do just that. It took 12 months to develop three prototypes of the device. They are man-sized devices, the larges one almost 2 meters (7 feet) tall. While developing the units, we started to network with African Governments in endemic areas to see whether we could run a test wit the devices. Finally we had the blessing of the Ghana Health Ministry. My right hand Konrad and myself traveled to Ghana in February of 2008 to start the tests.

How to get three large units into an African country is a science in itself, but we finally sailed around all cliffs and were ready to go. Our prototypal aim was to try the treatment with patients that had los levels of parasites, just to see whether there would be any adverse effects. We worked with 4 patients. There were no adverse effects, but also the before and after tests showed that malaria was cleared in a very short treatment time with our units!

We then went on to impact with a hospital to treat a larger number of patients -- the goal was to treat some 30 patients. After a some days we realized that we could not use those tests because the lab at the hospital unskilled al lour blood test slides. At the end of our time in Ghana, we had exclusive our prototypal 4 (but very good) results and the useless hospital experience. We did not hit the time to continue at that time but instructed a topical professional on how to use the machines.

Now our prototypal study is finished and 26 patients were treated. Out of the 26 patients, all except one became negative with the attractable treatment! One felt worse the day after treatment started and decided to go for medication instead, so he dropped out of the study. The another 25 patients all became negative. And the ones who did not hit high levels of parasites, were negative right after the prototypal 60 minutes of treatment! This is so fast that we do not really hit an explanation of how it could impact so quickly. But the results are nothing short of sensational.

Now our goal is to do a second study and to get others on board to turn this into a home unit for treatment of malaria.

NYSE Arca Morning Update - 08:30:00 ET

NYSE Arca Morning Update for Friday, Aug 28, 2009 :

STOCKS TRADING ON NYSE Arca AT A PRICE 15% OR MORE AWAY FROM
THE PREVIOUS TRADE DAY'S CONSOLIDATED CLOSE PRICE (AS OF 08:30:00 ET)

Stock Thursday's Close Current Price Pct Change Current NYSE ARCA Vol
SHS $5.99 $0.64 (89.3%) 2,100
SCSS $2.83 $4.25 50.2% 5,300
EURX $13.45 $17.97 33.6% 2,475
SVA $5.81 $7.14 23.0% 256,393
OVTI $13.29 $15.29 15.1% 2,330

10 MOST ACTIVE STOCKS ON NYSE ARCA AS OF 08:30:00 ET

BASED ON DOLLARS TRADED: | BASED ON SHARES TRADED:
Stock $ Volume Price PctChg | Stock Share Vol Price PctChg
SPY $102837986 $103.88 0.4% | C 7,651,889 $5.27 4.2%
AIG $49,799,927 $52.64 10.0% | FNM 2,721,707 $1.97 2.1%
C $40,323,038 $5.27 4.2% | CIT 1,311,255 $1.78 15.7%
GLD $15,577,376 $94.12 1.1% | SPY 989,700 $103.88 0.4%
NOK $9,781,067 $14.12 3.7% | AIG 954,802 $52.64 10.0%
DELL $8,007,036 $16.30 4.1% | ABK 863,134 $1.92 6.7%
AAPL $7,187,902 $171.81 1.4% | FRE 848,472 $2.33 4.0%
QQQQ $7,083,862 $40.53 0.3% | NOK 695,173 $14.12 3.7%
BAC $5,708,667 $18.14 1.2% | DELL 492,447 $16.30 4.1%
FNM $5,355,385 $1.97 2.1% | ETFC 367,260 $1.48 2.8%

Price changes may be affected by symbol splits and dividends.

Consolidated close price is the last print (excluding prints with trade
conditions) prior to 4PM ET.

This information is also updated on our web page every morning at 8:35ET:
http://www.tradearca.com/data/volume/daily_update.asp

This material is for informational purposes only.
NYSE Euronext and its affiliates ("NYSE Arca") are not soliciting any action based upon it.
This material is not to be construed as an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.
Any opinions expressed in this material are NYSE Arca opinions only.
NYSE Arca undertakes no obligation to update any of the information contained in this material in light of new information or future events.
THIS MATERIAL IS PROVIDED BY NYSE ARCA "AS IS" AND WITHOUT WARRANTIES EXPRESS OR IMPLIED.
NYSE ARCA DISCLAIMS ALL WARRANTIES INCLUDING THE IMPLIED WARRANTIES OF MERCHANTIBILITY, TITLE, AND FITNESS FOR A PARTICULAR PURPOSE AS TO THIS MATERIAL.
IN NO EVENT SHALL NYSE ARCA BE LIABLE FOR DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER (INCLUDING BUT NOT LIMITED TO, LOST PROFITS, TRADING LOSSES AND DAMAGES THAT MAY RESULT FROM THE USE
OF THIS MATERIAL, ANY DELAY OR INTERRUPTION OF SERVICE OR OMISSIONS OR INACCURACIES IN THE MATERIAL) WITH RESPECT TO THIS MATERIAL.

Copyright [2009] by NYSE Euronext. All rights reserved. Reproduction and redistribution prohibited without prior express consent.